Related Experiment Videos
Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series
Nicolas Aubut1, Jimmy Alain, Joël Claveau
1Department of Dermatology, Centre Hospitalier Universitaire de Québec, Quebec City, QC.
Background:
Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma.
Objective:
We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate.
Methods:
All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed.
Results:
Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur.
Limitations:
The follow-up period was short, and there was no histologic confirmation of the initial diagnosis.
Conclusion:
IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.